1.	Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Phase: Phase IV Type: Treatment Status: Completed Age: 40 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 102-12, NCT00090038
2.	Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Phase: Phase IV Type: Treatment Status: Completed Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL03, NCT00199004
3.	MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Phase: Phase IV Type: Treatment Status: Closed Age: 18 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: MO19872, NCT00430352
4.	LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Phase: Phase IV Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: 2006-003750-23, LINFOTARGAM, NCT00466258
5.	Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 20 to 69 Sponsor: Other Protocol IDs: JCOG0203, C000000033, NCT00147121
6.	Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IL2NHL03, UCLA-0302013, CHIR-IL2NHL03-A01, NCT00045877
7.	Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) With or Without Rituximab in Older Patients With Diffuse Mixed, Diffuse Large, or Immunoblastic Large Cell Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 60 and over Sponsor: NCI Protocol IDs: ECOG-E4494, E4494, CLB-9793, SWOG-E4494, NCT00003150
8.	Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SAKK 35/98, SWS-SAKK-35/98, ICR-35/98, EU-98009, NCT00003280
9.	Phase III Randomized Study of IDEC-Y2B8 Radioimmunotherapy Versus Rituximab Immunotherapy for Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: IDEC-106-04, MAYO-977802
10.	Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) With or Without Rituximab in Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: AMC-010, CPMC-IRB-9691, CWRU-AMC-1400, UCLA-9810029, NCT00003595
11.	Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IDEC-106-06, MAYO-987804, UCLA-9808026
12.	Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 19 and over Sponsor: NCI, Other Protocol IDs: 447-97, P30CA036727, UNMC-447-97, UCLA-HSPC-9812071, NCI-G99-1601, NCT00004112
13.	Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000067393, EORTC-20981, ALLG-NHLLOW4, BNLI-EORTC-20981, HOVON-H039, CAN-NCIC-LY7, NORDIC-EORTC-20981, LY7, NCT00004179
14.	Phase III Randomized Study of Rituximab Purging and Maintenance With Peripheral Blood Stem Cell Transplantation in Patients With Relapsed or Resistant Follicular Non-Hodgkin's Lymphoma Undergoing High-Dose Chemotherapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EBMT-EBMTLYM1, BNLI-EBMT-EBMTLYM1, EU-99050, NCT00005589
15.	S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068321, U10CA032102, S0016, CALGB-50102, SWOG-S0016, ECOG-SWOG-S0016, NCT00006721
16.	Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP), and Filgrastim (G-CSF) With or Without Rituximab in Elderly Patients With Intermediate or High-Risk Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 65 and over Sponsor: Other Protocol IDs: CKTO-2000-10, HOVON-46NHL, EU-20130, HOVON-CKVO-2000-10, NCT00028717
17.	Phase III Randomized Study of Autologous Stem Cell Transplantation With or Without Rituximab in Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 to 70 Sponsor: NCI Protocol IDs: ECOG-E2499, CALGB-50205, CALGB-E2499, NCT00052923, E2499
18.	Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Phase: Phase III Type: Health services research, Treatment Status: Closed Age: 61 to 80 Sponsor: Other Protocol IDs: CDR0000269015, DSHNHL-1999-1A, EU-20243, NCT00052936
19.	Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000346359, U10CA021115, ECOG-E4402, E4402, NCT00075946
20.	Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 16 to 65 Sponsor: Other Protocol IDs: LY12, CAN-NCIC-LY12, CDR0000353203, NCT00078949
21.	Phase III Randomized Study of Rituximab, Ifosfamide, Carboplatin, and Etoposide Versus Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Induction Therapy Followed By High-Dose Consolidation Chemotherapy and Autologous Stem Cell Transplantation With Versus Without Rituximab as Maintenance Therapy in Patients With Relapsed or Refractory CD20-Positive Diffuse Large B-Cell Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 to 65 Sponsor: NCI Protocol IDs: MSKCC-03139, CORAL-50-03B, NCT00137995
22.	FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 102-14, BO17072, NCT00090051
23.	Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SAKK 35/03, SWS-SAKK-35/03, EU-20520, CDR0000443594, NCT00227695
24.	Primary Rituximab and Maintenance Phase: Phase III Type: Treatment Status: Completed Age: over 18 Sponsor: Other Protocol IDs: PRIMA, NCT00140582
25.	ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Phase: Phase III Type: Treatment Status: Completed Age: 18 to 59 Sponsor: Pharmaceutical / Industry Protocol IDs: LNH03-2B, NCT00140595